Biocon And Mylan Get CRL From FDA For Lantus Rival

Biocon has run into fresh trouble with the US Food and Drug Administration after receiving a complete response letter on its application for insulin glargine, a proposed rival to Sanofi’s top-selling Lantus biologic. 

FDA
The FDA has issued a CRL on Biocon's insulin glargine • Source: Shutterstock

Biocon’s efforts to win US approval to market its key diabetes challenger to French drugmaker Sanofi’s blockbuster Lantus (insulin glargine) has hit another stumbling block, with the US Food and Drug Administration saying it will not accept the insulin glargine application, filed by partner Mylan, in its current form.

Biocon insisted in a statement it was confident that the latest development would not affect the timing of the US...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.